Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 5/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | MTOR | P42345 | 2/20 | 0.42 |
| ▸ | ALPL | P05186 | 3/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | BRD1 | O95696 | 2/20 | 0.39 |
| ▸ | BRPF1 | P55201 | 2/20 | 0.39 |
| ▸ | BRPF3 | Q9ULD4 | 2/20 | 0.39 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2118462 | 0.89 | PIK3CA (0.39) | ACLYHSD11B1PIK3CAMTORALPL | |
| SCHEMBL2121542 | 0.81 | ALDH1A1 (0.41) | ALPL | |
| SCHEMBL2119213 | 0.80 | ACLY (0.49) | ACLYHSD11B1PIK3CAMTORALPL | |
| SCHEMBL2119029 | 0.80 | ACLY (0.49) | ACLYHSD11B1PIK3CAMTORALPL | |
| SCHEMBL2117745 | 0.80 | ALDH1A1 (0.39) | ACLYPIK3CAMTOR | |
| SCHEMBL2119300 | 0.80 | ACLY (0.54) | ACLYHSD11B1PIK3CAMTORSCN9A | |
| SCHEMBL2118327 | 0.79 | HSD11B1 (0.56) | ACLYHSD11B1 | |
| SCHEMBL2119284 | 0.79 | TRIM24 (0.45) | ALPLBRD4 | |
| SCHEMBL2118052 | 0.79 | GHSR (0.42) | SCN9ABRD4 | |
| SCHEMBL2119861 | 0.78 | EDNRA (0.39) | MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095012-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE | ELARA PHARMACEUTICALS GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| EP-2382190-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE AS-INHIBITORS | European Molecular Biology Laboratory (EMBL) (DE) | 2011-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095012-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE | HIF1A, HIF1AN, EGLN3 | ACLY 1578/4885HSD11B1 3376/4885PIK3CA 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.